0.72
+0.0196(+2.80%)
Currency In USD
| Previous Close | 0.7 |
| Open | 0.7 |
| Day High | 0.72 |
| Day Low | 0.69 |
| 52-Week High | 9.09 |
| 52-Week Low | 0.6 |
| Volume | 46,393 |
| Average Volume | 319,772 |
| Market Cap | 3.17M |
| PE | -0.07 |
| EPS | -10.19 |
| Moving Average 50 Days | 0.84 |
| Moving Average 200 Days | 2.45 |
| Change | 0.02 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of April 19, 2025 at a share price of $0.72. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.2 as of April 19, 2025 at a share price of $0.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
GlobeNewswire Inc.
Apr 09, 2025 12:30 PM GMT
Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
GlobeNewswire Inc.
Mar 14, 2025 12:30 PM GMT
Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious adverse events (SAEs) and no treatment-emergent advers
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
GlobeNewswire Inc.
Mar 12, 2025 12:30 PM GMT
PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Pali
Data not available